Back to the main directory
EarningsPreview / Equity
- Itaú BBA on Brazil Banking & Financial Services: Refined Preferences Ahead of 2Q22 and 2H22 by Itau
- SAAB - H2 offers major potential triggers by Danske Bank Equity Research
- Evolution - Buy/SEK 1,690 (1,686): Strong game pipeline offsets weakening macro by Nordea
- New Wave Group - Buy/SEK 200 (220): Near-term outlook remains good by Nordea
- XXL Asa - Sell/NOK 5 (8.80): At the mercy of creditors unless earnings improve by Nordea
- Ferrovial - 2Q22 Results Preview: All eyes on traffic trends by JB Capital Markets
- WOOD Daily: Jumbo (stays BUY), FP RO, MIL PW, HTO GA, DIGI RO, WPL PW, ACP PW by Wood and Company
- AstraZeneca - Buy/SEK 1,582 (1,591): A stepping stone to new catalysts in H2 2022 by Nordea
- Nokia - Buy/EUR 6.50: Set to outperform peers amid inflationary pressure by Nordea
- Stora Enso - Hold: Q2 earnings risk tilted to the upside by Nordea
- Cellnex Telecom - 2Q22 Results Preview: Looking for guidance reiteration after German exit; we maintain Buy by JB Capital Markets
- Redeia - LatAm and Hispasat improve slightly; Underweight by JB Capital Markets
- Sinch - Look for cash flow, look for volume growth by Danske Bank Equity Research
- Kone - The bad news is now out by Danske Bank Equity Research
- F-Secure - Buy/EUR 3.10: Independent debut in the spotlight by Nordea
- Rovi - 2Q22 Results Preview: Covid-19 vaccines production to accelerate in 2H22; reiterating Buy by JB Capital Markets
- Renta Corporación - 2Q22 Preview: Expect good results and key messages in call by JB Capital Markets
- Itaú BBA on Brazil Homebuilders: 2Q22 Operational Preview – Tenda & Trisul by Itau
- Lemonsoft - Acquisitions support 2022-23 growth by Danske Bank Equity Research
- Ringkjøbing Landbobank - Strong core trends set to be key by Danske Bank Equity Research
- Humana - Buy/SEK 70 (75): Weak Q2 should mark an operational trough by Nordea
- Oriola - Buy/EUR 2.50 (2.60): Market has remained favourable by Nordea
- UPM-Kymmene - Buy/EUR 40: Earnings rebound to continue despite uncertainties by Nordea
- Faes Farma - 2Q22 Results Preview: Positive business evolution but awaiting news on future strategy; we reiterate Neutral by JB Capital Markets
- YIT - Too early to jump in by Danske Bank Equity Research